Idera Pharmaceuticals Inc


Idera Pharmaceuticals Inc (IDRA) Rebuilds Cancer Drug Hopes with New Melanoma Data

Today, Idera Pharmaceuticals Inc (NASDAQ:IDRA) investors woke up to a nice pop in the value of their shares, after the drug maker presented …

A Glimpse Into Soaring Biotech Stocks: AVEO Pharmaceuticals, Inc. (AVEO), Idera Pharmaceuticals Inc (IDRA)

AVEO Pharmaceuticals Shares Skyrocket on Positive CHMP Opinion It’s a very rewarding trading day for investors in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) with shares up over …

Idera Pharmaceuticals Inc (IDRA) Reports Additional Phase 1/2 Data In Metastatic Melanoma

Idera Pharmaceuticals Inc (NASDAQ:IDRA) is reporting additional data from the dose-escalation phase of its ongoing Phase 1/2 clinical trial of intratumoral IMO-2125, an agonist …

Stock Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development

Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced the appointment of Jonathan Yingling, Ph.D.

Cowen Bullish on Idera Pharmaceuticals Inc (IDRA) Following IMO-9200 Licensing Deal

This morning, Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced a licensing and collaboration agreement with Vivelix for rights to develop and market IMO-9200, a TLR …

Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc and VIvelix Pharmaceuticals, Ltd. Enter into Exclusive License Agreement for the Worldwide Rights to IMO-9200

Idera Pharmaceuticals Inc (NASDAQ:IDRA) and Vivelix Pharmaceuticals, Ltd. announced that they have entered into an exclusive license and collaboration agreement granting Vivelix worldwide …

Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125

Idera Pharmaceuticals Inc (NASDAQ:IDRA) is reporting translational data supporting the mechanism of action of intratumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist from …

Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Reports 3Q:16 Financial Results

Idera Pharmaceuticals Inc (NASDAQ:IDRA) reported its financial and operational results for the third quarter ended September 30, 2016. Since June 30, 2016, the Company: …

Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Announces Pricing of Public Offering of Common Stock

Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced the pricing of an underwritten public offering of 25,000,000 shares of common stock for a public offering price of …

Company Update (NASDAQ:IDRA): Here’s Why Idera Pharmaceuticals Shares Plunged 12% Today

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced yesterday that it intends to offer and sell up to $50,000,000 of shares of its common stock in …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts